Liquid Biopsy Market – Global Outlook & Forecast 2023-2028

MARKET OUTLOOK

The global liquid biopsy market was valued at USD 3.48 billion in 2022 and is expected to reach USD 12.16 billion by 2028, growing at a CAGR of 23.19%. The primary application of liquid biopsy lies in the field of oncology. It enables early cancer detection, facilitates personalized treatment decisions, monitors treatment response, detects minimal residual disease, and aids in identifying emerging mutations and therapeutic targets. The liquid biopsy market is also promising for diagnosing and monitoring other diseases, including infectious diseases, cardiovascular disorders, and prenatal screening. Several technologies are employed in liquid biopsy, including next-generation sequencing (NGS), PCR, mass spectrometry, and microfluidics. These advanced techniques enable the detection and characterization of rare tumor-specific genetic alterations and other biomarkers in a minimally invasive manner.

Liquid biopsy has emerged as a ground-breaking and non-invasive medical diagnostic approach, offering a revolutionary method for detecting and monitoring diseases, particularly cancer. Unlike traditional tissue biopsies, which require invasive procedures, liquid biopsy involves the analysis of biomarkers present in various biofluids, such as blood, urine, or cerebrospinal fluid. This innovative technique has garnered immense attention and is transforming the landscape of precision medicine and oncology. The liquid biopsy market can revolutionize how diseases, especially cancer, are diagnosed, monitored, and treated. It offers several advantages over conventional tissue biopsies, including its non-invasive nature, its ability to provide real-time and dynamic information about the disease, and the possibility of capturing tumor heterogeneity. By detecting and analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers, liquid biopsy provides insights into genetic alterations, tumor mutations, treatment response, minimal residual disease, and the development of resistance.

While liquid biopsy has garnered significant attention and demonstrated its potential, challenges remain to be addressed. Technical limitations, such as the sensitivity and specificity of assays, standardization of protocols, and data interpretation, are areas of ongoing research. Regulatory considerations, reimbursement policies, and integration into clinical practice also challenge the liquid biopsy market. Despite these challenges in the liquid biopsy market, the rapid advancements in technology, increasing clinical evidence, and growing investments in research and development are propelling the liquid biopsy field forward. As the understanding of the molecular mechanisms of diseases deepens and technology continues to improve, the liquid biopsy market holds immense promise for revolutionizing diagnostics, patient management, and therapeutic decision-making across various medical specialties.

MARKET TRENDS & DRIVERS

Increasing Role of Liquid Biopsy as a Companion Diagnostics
As liquid biopsy technologies continue to advance, their role as companion diagnostics is expanding rapidly. The non-invasive nature, ability to capture tumor heterogeneity and dynamics, early detection of MRD, real-time treatment response assessment, targeted therapy selection, and biomarker discovery make liquid biopsy an invaluable tool in guiding personalized treatment strategies. The integration of liquid biopsy as a companion diagnostic is transforming the field of precision medicine, leading to more effective and tailored therapeutic approaches for patients.

New Product Launches
The liquid biopsy market has witnessed several notable product launches in recent years. Companies like Guardant Health, Roche, and Illumina have introduced innovative solutions to enhance liquid biopsy capabilities. These include new liquid biopsy assays with expanded gene panels, improved sensitivity, and increased accuracy. Advanced platforms and technologies, such as digital PCR and next-generation sequencing (NGS), have also been introduced to enable more comprehensive and precise analysis of circulating biomarkers. Bioinformatics tools and software have also been developed to facilitate data analysis and interpretation, enhancing the clinical utility of liquid biopsy.

Higher Patient Preference for Non-invasive Diagnosis and Monitoring
The preference for non-invasive diagnosis and monitoring methods has become a significant driver for the liquid biopsy industry. Patients and healthcare providers increasingly recognize the advantages of liquid biopsy over invasive tissue biopsies, such as reduced procedural risks, minimal discomfort, and the ability to obtain multiple samples over time. Liquid biopsy's non-invasive nature also allows for easier accessibility, especially in cases where obtaining tissue biopsies may be challenging or impractical. The growing demand for non-invasive diagnostic approaches aligns with the convenience, safety, and potential for real-time monitoring offered by liquid biopsy, contributing to its expanding adoption and market growth.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT
The kits & reagents product segment dominated the global liquid biopsy market and is projected to witness the fastest growth rate of over 23% during the forecast period. Liquid biopsy kits and reagents are tools used to detect and diagnose cancer. Liquid biopsy kits and reagents are designed to detect and analyze specific biomarkers in the blood, urine, saliva, or other bodily fluids. Different reagents may be used to identify and measure the biomarkers depending on the type of liquid sample used. Overall, liquid biopsy kits and reagents have revolutionized the field of cancer detection and diagnosis. With these tools, clinicians can now detect and diagnose cancer more accurately, quickly, and cost-effectively than ever before.

INSIGHTS BY SAMPLE TYPE
The global liquid biopsy market by sample type segments as blood and others. The blood segment held the largest global market share. The development of liquid biopsy has revolutionized medical diagnostics and changed how we approach disease treatment. Liquid biopsy is a type of biopsy procedure involving the extraction of genetic material from a patient’s blood or other bodily fluid for disease diagnosis and prognosis. One of the most common and widely used liquid biopsy methods is the analysis of blood samples.

INSIGHTS BY APPLICATION
The global liquid biopsy market by application segments by cancer and non-cancer.The cancer segment accounted for the largest global liquid biopsy market share. Cancer is a major health concern, and its early detection is critical for successful treatment. Unfortunately, traditional invasive biopsies are often painful, expensive, and not always suitable for cancer detection. As a result, liquid biopsy has emerged as an attractive alternative, offering the potential to detect cancer earlier and with less risk. A liquid biopsy is a minimally invasive procedure that analyzes molecules in body fluids such as blood or urine to detect cancer. By analyzing cancer-specific molecules, such as circulating tumor DNA, commonly known as ctDNA, or circulating tumor cells, liquid biopsies can accurately diagnose cancer before the tumor becomes visible.

INSIGHTS BY BIOMARKER TYPE
The cfDNA & ctDNA biomarker type segment dominated the global liquid biopsy market, accounting for over 41% in 2022. Cell-free DNA (cfDNA) is a rapidly developing technology in liquid biopsy that has opened up a new field of cancer diagnosis and patient management. It involves DNA extraction from a sample of circulating blood, which can then be analyzed for the presence of genetic mutations. These mutations are associated with cancer development and can provide a detailed picture of a patient’s disease.

INSIGHTS BY TECHNOLOGY
The next-generation sequencing (NGS) technology segment dominated the global liquid biopsy market in 2022. Liquid biopsy is a revolutionary technique that has transformed the field of cancer diagnosis and treatment. In particular, liquid biopsy has greatly advanced the study of cancer genomics using NGS. NGS is a powerful and cost-effective technology that enables the rapid sequencing of large amounts of genetic material. NGS sequences the sample's genetic material and identifies any cancer-related mutations. Through this process, researchers can detect cancer at earlier stages and determine the type and aggressiveness of the cancer. The data generated from NGS can be used to develop targeted therapies and improve patient outcomes.

INSIGHTS BY END-USER
The hospital end-user segment accounted for the largest global liquid biopsy market share. As medical technology advances, liquid biopsy in hospitals is becoming more commonplace. Liquid biopsy is a relatively new technology that utilizes a patient’s blood, urine, or other body fluids to detect cancer cells or biomarkers. This method offers an alternative to traditional tissue biopsies, which are invasive, painful, and expensive. By detecting cancer cells or markers from a simple blood or urine sample, liquid biopsy can provide non-invasive, cost-effective, and timely diagnostic information. The use of liquid biopsy in hospitals is increasing due to its versatility and convenience. It can detect various cancers, including breast, colorectal, lung, prostate, and ovarian. It can also detect cancer at earlier stages, providing earlier diagnosis and treatment. Using liquid biopsy for cancer detection is also beneficial because it can monitor real-time response to treatment, such as chemotherapy or immunotherapy.

GEOGRAPHICAL ANALYSIS

North America dominated the global liquid biopsy market share, accounting for over 48% in 2022. The increasing demand for liquid biopsy technology in North America comes in the face of growing cancer rates across the U.S. and Canada, as well as an increased awareness of the early diagnostic benefits of this technology. Liquid biopsies can provide detailed information on the presence of the disease, its type, and its progression in the body much earlier than traditional methods and procedures.

The growth of the global liquid biopsy market is among Europe's most disruptive developments in cancer treatments. Since it involves a non-invasive testing method, liquid biopsy can be extremely beneficial for elderly or fragile patients, as it reduces the risk of complications arising from sampling tissue from the body. This makes it one of the best and most efficient options for early detection of cancerous cells in these patients, and as a result, many European governments have started to invest widely in its research. In addition, due to the enhanced accuracy of liquid biopsy testing compared to mechanical biopsies, its use is now more widely accepted among medical professionals in many European countries.

COMPETITIVE LANDSCAPE

Competing in the global liquid biopsy market demands robust clinical validation and regulatory approvals. Companies that successfully navigate regulatory pathways, obtain approvals from health authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and provide solid clinical evidence gain a competitive advantage. Validated assays with regulatory endorsements instill confidence in healthcare professionals and contribute to industry penetration. Continuous advancements in sequencing technologies, digital PCR, and other analytical platforms have improved the sensitivity and specificity of liquid biopsy tests. These advancements enhance the ability to detect rare mutations and monitor tumor heterogeneity.

The global liquid biopsy market is highly competitive, with key players focused on developing innovative solutions and expanding their market presence. Advancements in technology, increasing clinical adoption, and strategic collaborations are shaping the landscape of this dynamic industry. Key players in the global liquid biopsy market are forming strategic partnerships and collaborations with pharmaceutical companies, research institutions, and diagnostic laboratories. Further, these partnerships aim to leverage complementary expertise, expand market reach, and accelerate the development of novel liquid biopsy assays.